DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
von Minckwitz G, Timms K, Untch M. et al.
Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer.
Cancer Res; 2017
77. Abstr. P1-09-02
Access:
We do not assume any responsibility for the contents of the web pages of other providers.